Literature DB >> 22237166

Ketamine-like effects after recreational use of methoxetamine.

Katharina E Hofer1, Bettina Grager, Daniel M Müller, Christine Rauber-Lüthy, Hugo Kupferschmidt, Katharina M Rentsch, Alessandro Ceschi.   

Abstract

Methoxetamine, the N-ethyl derivative of ketamine, is a novel recreational drug that is not at present subject to restrictive regulations in most countries. To our knowledge, no case of methoxetamine abuse has been published to date in the scientific literature, and the only sources of information are illegal drug users' Web discussion forums. We report the first case of analytically confirmed intravenous methoxetamine abuse in a 19-year-old man. Observed signs and symptoms such as tachycardia, hypertension, confusion, agitation, stupor, ataxia, mydriasis, and nystagmus were consistent with ketamine-induced adverse effects and resolved with symptomatic treatment. According to this case report, user Web reports, and the chemical structure, methoxetamine produces ketamine-like effects. Complete recovery can be expected with supportive care.
Copyright © 2011. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237166     DOI: 10.1016/j.annemergmed.2011.11.018

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  10 in total

1.  Methoxetamine affects brain processing involved in emotional response in rats.

Authors:  M T Zanda; P Fadda; S Antinori; M Di Chio; W Fratta; C Chiamulera; L Fattore
Journal:  Br J Pharmacol       Date:  2017-08-19       Impact factor: 8.739

2.  Phencyclidine-like in vivo effects of methoxetamine in mice and rats.

Authors:  Michael D Berquist; William S Hyatt; Jonathan Bauer-Erickson; Brenda M Gannon; Andrew P Norwood; William E Fantegrossi
Journal:  Neuropharmacology       Date:  2017-08-19       Impact factor: 5.250

3.  The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission.

Authors:  Anna Mutti; Sonia Aroni; Paola Fadda; Laura Padovani; Laura Mancini; Roberto Collu; Anna Lisa Muntoni; Liana Fattore; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2016-03-28       Impact factor: 4.530

Review 4.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

5.  Methoxetamine (MXE)--a phenomenological study of experiences induced by a "legal high" from the internet.

Authors:  Anette Kjellgren; Kristoffer Jonsson
Journal:  J Psychoactive Drugs       Date:  2013 Jul-Aug

6.  Ketamine Analog Methoxetamine Induced Inflammation and Dysfunction of Bladder in Rats.

Authors:  Qiang Wang; Qinghui Wu; Junpeng Wang; Yang Chen; Guihao Zhang; Jiawei Chen; Jie Zhao; Peng Wu
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

Review 7.  Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs.

Authors:  Francesco Paolo Busardo; Simona Pichini; Manuela Pellegrini; Angelo Montana; Alfredo Fabrizio Lo Faro; Simona Zaami; Silvia Graziano
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  "Being with a Buddha": A Case Report of Methoxetamine Use in a United States Veteran with PTSD.

Authors:  Joan M Striebel; Emily E Nelson; Raj K Kalapatapu
Journal:  Case Rep Psychiatry       Date:  2017-01-29

9.  The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor.

Authors:  Bryan L Roth; Simon Gibbons; Warunya Arunotayanun; Xi-Ping Huang; Vincent Setola; Ric Treble; Les Iversen
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

Review 10.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.